Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TST002 in Postmenopausal Osteoporosis and Low Bone Mass
NCT07806331Phase 2Not yet recruiting
- Sponsor
- Transcenta
- Start
- Oct 2026
- Primary completion
- Apr 2027
01
Overview
A Phase 2 trial of blosozumab in postmenopausal osteoporosis, osteopenia, sponsored by Transcenta. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
blosozumab
03
Conditions
postmenopausal osteoporosisosteopenia
Beyond the preview
Go deeper on NCT07806331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07806331.